{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-047196","form_type":"8-K","ticker":"CABA","cik":"0001759138","company_name":"Cabaletta Bio, Inc.","filed_at":"2025-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.752392+00:00","generated_at":"2026-05-24T02:01:40.414416+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cabaletta Bio Q4/FY2024 results: cash $164M, R&D spend up, protocol deviation in SSc trial","bullets":["Cash and equivalents $164M as of Dec 31, 2024, providing runway into first half of 2026.","R&D expenses for FY2024 were $97.2M, up from $55.4M in FY2023.","Enrolled 33 patients across RESET program as of Mar 14, 2025; FDA meeting on myositis trial designs on track for 1H25.","Protocol deviation in RESET-SSc: patient infused with fever developed grade 3 ICANS; IDMC recommended trial continue.","Expanded CDMO agreement with Lonza for rese-cel clinical product supply starting 2H25."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-047196","json":"https://secwatch.observer/filing/0000950170-25-047196.json","markdown":"https://secwatch.observer/filing/0000950170-25-047196.md","text":"https://secwatch.observer/filing/0000950170-25-047196.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1759138/000095017025047196/0000950170-25-047196-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1759138/000095017025047196/caba-20250331.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T02:01:40.414416+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}